3C-DFM

3C-DFM, also known as 4--3,5-dimethoxyamphetamine or as or as α-methyldifluoromescaline, is a serotonin receptor modulator of the phenethylamine and 3C families. It is the amphetamine derivative of the psychedelic drug difluoromescaline. The properties and effects of 3C-DFM in humans are unknown. The drug shows affinity for the serotonin 5-HT₂ receptors and is known to act as an agonist of the serotonin 5-HT_2A and 5-HT_2B receptors. 3C-DFM was first described in the scientific literature by Daniel Trachsel by 2012. It is a controlled substance in Ukraine. The drug is also a controlled substance in Canada under phenethylamine blanket-ban language.